argenx at EBF 2026

Nov 17–19, 2026 Barcelona, Spain ~800 attendees Website

argenx brings 2 presentations to EBF 2026 in Barcelona. Its program covers a streamlined ADA strategy for a biologic entering clinical development and turning a qualitative diagnostic assay into a semi-quantitative titer assay.

Organization	EBF 2026 Attendance
argenx
argenx.com Biotech Immunology biotech whose antibody efgartigimod treats generalized myasthenia gravis and other autoimmune diseases.	Talk Tue Nov 17 5:40–6pm Part of Session 7: BM CoU in practice From qualitative detection to quantitative insight: repurposing a diagnostic assay into a fit-for-purpose semi-quantitative titer assay as measure of treatment response Biomarkers Talk Wed Nov 18 11:40am–12pm Part of Session 14: Rethinking ADA Assessment, Context, Evidence and Evolving Expectations - part 2 A streamlined ADA testing strategy to assess the clinical immunogenicity of a biological drug entering clinical development Immunogenicity

Organization

EBF 2026 Attendance

argenx

argenx.com

Biotech

Immunology biotech whose antibody efgartigimod treats generalized myasthenia gravis and other autoimmune diseases.

Talk

Tue Nov 17
5:40–6pm

Part of Session 7: BM CoU in practice

From qualitative detection to quantitative insight: repurposing a diagnostic assay into a fit-for-purpose semi-quantitative titer assay as measure of treatment response

Biomarkers

Talk